Internal Contact Information
Dr. Chow is Research Professor of Medicine at the University of Arizona. She is a translational scientist involved in early phase clinical development of cancer chemopreventive agents and development of biochemical and molecular biomarkers for evaluation of cancer risk and drug efficacy. She has been a member of the University of Arizona Cancer (UACC) Cancer Prevention and Control (CPC) Program and been continuously funded for cancer-related research since 1999.
Dr. Chow has co-directed the UACC Analytical Chemistry Shared Resource (ACSR) since 2001. She is the Principal Investigator (PI) for the University of Arizona Early Phase Chemoprevention Consortium. The UA consortium is one of only five awardees selected by NCI, Division of Cancer Prevention (DCP) to conduct early phase clinical trials of NCI, DCP-sponsored chemopreventive agents. The Consortium consists of a team of clinicians and translational researchers from the University of Arizona and other member institutions, including Stanford, Emory, University of North Carolina, Ohio State University, University of Southern California, University of California Irvine, University of California San Diego, Cedars Sinai, Johns Hopkins, NRG, and Southern Arizona VA health Care System. The completed and planned consortia trials encompass evaluation of pharmaceutical and nutraceutical agents for lung, breast, cervix, prostate, melanoma, skin and esophageal cancer prevention. For the development and performance of each of these trials, he has facilitated the collaboration and coordinated the interactions among clinicians, translational scientists, and NCI, DCP program staff. he has also served as the PI for grants funded by NCI and DOD to study the clinical activity of limonene and metformin for breast cancer prevention.
Dr. Chow also serves as Co-Investigator on multiple federally-funded research projects in cancer prevention or treatment. She is the co-author of more than 70 peer-reviewed journal articles published in major Cancer journals. In addition, she has been involved in the development of chromatography-mass spectrometry assays for various drugs, nutrients, bioactive food components, and endogenous biochemicals in various biological specimens. Recently, she has applied comprehensive metabolic profiling to specimens collected from our chemoprevention trials to examine the mechanisms of action of putative chemopreventive agents and to discover new biomarkers for future studies.
Dr. Chow has mentored dozens of graduate students, medical students, research fellows, and junior faculty in cancer chemoprevention and analytical chemistry methods, served on the advisory board for the Cancer Prevention and Control R25T training grant and led several funded projects that engaged novel groups of inter- and intra-programmatic faculty. She has the professional experience, leadership skills, and motivation necessary to lead the CPC Program and the ACSR at UACC.
Dr. Chow has served as the Principal Investigator on multiple research projects funded by major federal agencies including the National Cancer Institute, Department of Defense, and National Institute on Drug Abuse. She also serves as Co-Investigator on multiple large federally funded research projects. Since joining the UA Cancer Center in 1999, Dr. Chow’s research has focused on early phase clinical development of potential cancer chemopreventive agents, including green tea polyphenols, resveratrol, and limonene. Her research activities include evaluation of the clinical pharmacokinetics and cancer preventive activities of potential cancer chemopreventive agents, examination of factors affecting the bioavailability of cancer chemopreventive agents, examination of the metabolic interactions of chemopreventive agents and drugs, and development of surrogate biomarkers for early phase clinical assessment of drug effects.
Dr. Chow has authored and co-authored 50 peer-reviewed journal articles published in major Cancer or Pharmaceutical journals. She is a member of the University of Arizona Cancer Center and directs the UA Cancer Center Analytical Core Shared Service.
Dr Chow’s current research focuses on early phase clinical development of potential cancer chemopreventive agents, including green tea polyphenols, resveratrol, and limonene.
One of Dr. Chow’s key research areas is early phase clinical development of green tea polyphenol extract for cancer prevention. Her research program has been funded by NCI to conduct a series of clinical trials to determine the clinical safety, pharmacokinetics, pharmacodynamics, and drug-drug interactions of a defined green tea polyphenol extract. These data were published in major cancer journals such as Clinical Cancer Research and Cancer Epidemiology Biomarkers & Prevention. Some of the recent findings have received extensive media coverage at the local, national, and international levels. In collaboration with UA researchers, multiple Phase II cancer prevention trials of green tea extract are being conducted at the Arizona Cancer Center. She serves as a key investigator for these trials, contributing significantly to all aspects of these studies. The outcome of these clinical studies will serve as the groundwork for defining the cancer preventive activities of green tea extract.
Dr. Chow also serves as the Principal Investigator of the UA Phase I/II Chemoprevention Consortium. This consortium is funded by a major NCI research contract to conduct multiple early phase clinical trials of chemopreventive agents. The UA consortium is one of only six institutions nationwide selected for this competitive award. She has established a Consortium office staffed with clinical coordinators, research assistants and data management staff in support of such trials. The ongoing and planned trials encompass the clinical development of potential chemopreventive agents for breast, cervix, prostate, melanoma, and esophageal cancer prevention. Through the conduct and planning of these trials, she has formed alliances with outside institutions and involved multiple UA medical sub-specialists.
The Analytical Core Shared Service, which Dr. Chow directs, provides analytical services to help assess drug or nutrient exposure and disposition, and to monitor the levels of endogenous biochemicals as surrogate biological effect markers. These are all critically important to the development and evaluation of innovative pharmacological and nutritional approaches to treating and preventing cancer.
- Chow, H-H.S., Yan, C., Alberts, D.S., Hakim, I., Dorr, R., Shahi, F., Crowell, J.A., Yang, C.S., and Hara, Y. “ Phase I pharmacokinetic study of tea polyphenols following single dose administration of epigallocatechin gallate and Polyphenon E.” Cancer Epidemiology Biomarkers & Prevention, 10:53-58, 2001.
- Chow, H-H.S., Dalazar D., and Hakim, I.A. “Pharmacokinetics of perillic acid in humans following a single dose administration of a citrus preparation rich in d-limonene content.” Cancer Epidemiology, Biomarkers & Prevention, 11:1472-1476, 2002.
- Chow, H-H.S., Cai, Y., Hakim, I.A., Crowell, J.A., Shahi, F., Brooks, C.A., Dorr, R.T., Hara, Y., and Alberts, D.S. “Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and Polyphenon E in healthy individuals.” Clinical Cancer Research, 9:3312-3319, 2003.
- Hakim, I.A., Harris, R.B., Brown, S., Chow, H-H.S., Wiseman, S., Agarwal, S., and Talbot, W. “Effect of increased tea consumption on oxidative DNA damage among smokers: a randomized controlled study.” Journal of Nutrition, 133:3303S-3309S, 2003.
- Hakim, I.A., Harris R.B., Chow, H-H.S., Dean, M., Brown, S., and Ali, I.U. “Effect of a 4-month tea intervention on oxidative DNA damage among heavy smokers: role of glutathione S-transferase genotypes.” Cancer Epidemiology, Biomarkers & Prevention, 13:242-249, 2004.
- Chow, H-H.S., Hakim, I.A.,Vining, D.R.,Crowell, C.A., Ranger-Moore, J.,Chew, W.M., Celaya, C.A., Rodney, S.R., Hara, Y., Alberts, D.S. “Effects of Dosing Condition on the Oral Bioavailability of Green Tea Catechins after Single-Dose Administration of Polyphenon E in Healthy Individuals.” Clinical Cancer Research, 11:4627-4633, 2005.
- Chow, H-H.S., Hakim, I.A.,Vining, D.R.,Crowell, J.A., Cordova, C.A., Chew, W.M., Xu, M-J., Hsu, C-H., Ranger-Moore, J., Alberts, D.S. “Effects of Repeated Green Tea Catechin Administration on Human Cytochrome P450 Activity.” Cancer Epidemiology Biomarkers & Prevention, 15:2473-2476, 2006.
- Chow, H-H.S., Hakim, I.A.,Vining, D.R.,Crowell, J.A., Tome, M.E., Ranger-Moore, J., Cordova, C.A., Mikhael, D.M., Briehl, M.M., , Alberts, D.S. “Modulation of Human Glutathione S-Transferases by Polyphenon E Intervention.” Cancer Epidemiology Biomarkers & Prevention, 16:1662-1666, 2007.
- Hakim, I.A., Chow, H-H.S., Harris, R.B. “Green tea consumption is associated with decreased DNA damage among GSTM1-positive smokers regardless of their hOGG1 genotype.” Journal of Nutrition, 138:1567S-1571S, 2008.
- Miller, J.A., Hakim, I.A., Thomson, C., Thompson, P., Chow, H-H.S. “Determination of d-limonene in adipose tissue by gas chromatography-mass spectrometry.” Journal of Chromatography B, 870: 68-73, 2008.
- Dragovich, T., Burris, H., Loehrer, P., Von Hoff, D.D., Chow, H-H.S., Stratton, S., Green, S., Obregon, Y., Alvarez, I., Gordon, M. Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma." American Journal of Clinical Oncology, 31:157-162, 2008.
- Shaw, A., Henderson, M.C., Flynn, G., samulitis, B., Han, H., Stratton, S., Chow, H-H.S., Hurley, L.H., Dorr, R.T. "Characterization of novel diaryloxazone-based compounds as potential agents to treat pancreatic cancer." Journal of Pharmacology and Experimental Therapeutics, 331:636-647, 2009.
- Thompson, P., Hsu, C-H., Green, S., Stopeck, A., Johnson, K., Alberts, D., Chow, H-H.S. "Sulindac and sulindac metabolites in nipple aspirate fluid and effect on drug targets in a Phase I trial," Cancer Prevention Research, 3:101-107, 2010.